Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy
Details
Publication Year 2022-10,Volume 63,Issue #10,Page 2364-2374
Journal Title
Leukemia & Lymphoma
Publication Type
Review
Abstract
Chimeric antigen receptor T-cell (CAR-T) therapy is a promising immunotherapy approved for hematological malignancies. Despite its effectiveness, clinically significant rates of toxicity, including immune effector cell associated neurotoxicity syndrome (ICANS), limit its widespread use. In certain contexts, ICANS may occur in up to one-third of patients using commercially available CAR-T therapies. The syndrome presents with a range of neurological signs and symptoms, as well as a variety of neuroimaging manifestations reported in the literature. A systematic review of the literature was performed. The systematic search strategy identified 24 studies discussing the neuroimaging appearances associated with ICANS. Imaging findings are more common in patients with higher grade neurotoxicity. The neuroimaging findings are heterogeneous, but can be grouped either anatomically (white matter, gray matter, brainstem, or leptomeninges) or pathologically (ischemic changes, hemorrhages, or cerebral edema). An understanding of the imaging manifestations of ICANS has the potential to impact the management of patients.
Keywords
Cell- and Tissue-Based Therapy; Humans; Immunotherapy, Adoptive/adverse effects/methods; Neuroimaging; *Neurotoxicity Syndromes/diagnostic imaging/etiology; *Receptors, Chimeric Antigen/therapeutic use; Chimeric antigen receptor T-cell therapy; hematological malignancies; immune effector cell associated neurotoxicity syndrome; magnetic resonance imaging
Department(s)
Haematology; Cancer Imaging
PubMed ID
35570737
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2025-01-09 06:52:44
Last Modified: 2025-01-09 06:54:51

© 2025 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙